Industry
Biotechnology
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
April 17, 2024 | 5:35 pm
Portfolio Pulse from Benzinga Newsdesk
April 17, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
April 10, 2024 | 11:14 am
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 6:28 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 1:02 pm
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 4:12 pm
Portfolio Pulse from Happy Mohamed
March 26, 2024 | 1:28 pm
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 1:13 pm
Portfolio Pulse from Benzinga Insights
March 26, 2024 | 1:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.